npj Precision Oncology (Jun 2021)

Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy

  • Martin Thelen,
  • Kerstin Wennhold,
  • Jonas Lehmann,
  • Maria Garcia-Marquez,
  • Sebastian Klein,
  • Elena Kochen,
  • Philipp Lohneis,
  • Axel Lechner,
  • Svenja Wagener-Ryczek,
  • Patrick Sven Plum,
  • Oscar Velazquez Camacho,
  • David Pfister,
  • Fabian Dörr,
  • Matthias Heldwein,
  • Khosro Hekmat,
  • Dirk Beutner,
  • Jens Peter Klussmann,
  • Fabinshy Thangarajah,
  • Dominik Ratiu,
  • Wolfram Malter,
  • Sabine Merkelbach-Bruse,
  • Christiane Josephine Bruns,
  • Alexander Quaas,
  • Michael von Bergwelt-Baildon,
  • Hans A. Schlößer

DOI
https://doi.org/10.1038/s41698-021-00196-x
Journal volume & issue
Vol. 5, no. 1
pp. 1 – 12

Abstract

Read online

Abstract The immune response against cancer is orchestrated by various parameters and site-dependent specificities have been poorly investigated. In our analyses of ten different cancer types, we describe elevated infiltration by regulatory T cells as the most common feature, while other lymphocyte subsets and also expression of immune-regulatory molecules on tumor-infiltrating lymphocytes showed site-specific variation. Multiparametric analyses of these data identified similarities of renal and liver or lung with head and neck cancer. Co-expression of immune-inhibitory ligands on tumor cells was most frequent in colorectal, lung and ovarian cancer. Genes related to antigen presentation were frequently dysregulated in liver and lung cancer. Expression of co-inhibitory molecules on tumor-infiltrating T cells accumulated in advanced stages while T-cell abundance was related to enhanced expression of genes related to antigen presentation. Our results promote evaluation of cancer-specific or even personalized immunotherapeutic combinations to overcome primary or secondary resistance as major limitation of immune-checkpoint inhibition.